Enhanced anti-hepatoma effect of a novel curcumin analog C086
Animals
Antineoplastic Agents
/ administration & dosage
Calorimetry, Differential Scanning
Carcinoma, Hepatocellular
/ drug therapy
Cell Line, Tumor
Curcumin
/ administration & dosage
Drug Stability
HSP90 Heat-Shock Proteins
/ antagonists & inhibitors
Liver Neoplasms
/ drug therapy
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Rats
Rats, Sprague-Dawley
Solubility
Spectroscopy, Fourier Transform Infrared
Technology, Pharmaceutical
/ methods
Curcumin analog C086
anti-hepatoma
in vivo bioavailability
liver accumulation
solid dispersion
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
The novel curcumin analog C086, previously identified as an oral novel heat shock protein 90 (Hsp90) inhibitor, was found to exhibit anti-hepatoma activity
Identifiants
pubmed: 32597247
doi: 10.1080/10717544.2020.1785051
pmc: PMC8216446
doi:
Substances chimiques
Antineoplastic Agents
0
HSP90 Heat-Shock Proteins
0
curcumin analog C086
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
927-937Références
Pharmacol Rev. 2013 Jan;65(1):315-499
pubmed: 23383426
Nat Protoc. 2015 Aug;10(8):1264-74
pubmed: 26203823
Nat Rev Drug Discov. 2014 Dec;13(12):928-42
pubmed: 25435214
J Control Release. 2019 Dec 28;316:359-380
pubmed: 31682912
Acta Pharmacol Sin. 2018 Apr;39(4):649-658
pubmed: 29219946
Future Med Chem. 2015;7(3):269-89
pubmed: 25826360
Res Pharm Sci. 2010 Jan;5(1):49-56
pubmed: 21589768
J Cell Biochem Suppl. 1996;26:54-71
pubmed: 9154168
Int J Pharm. 2004 Mar 19;272(1-2):1-10
pubmed: 15019063
Biomaterials. 2004 Jul;25(16):3259-66
pubmed: 14980420
J Control Release. 2018 Dec 28;292:172-182
pubmed: 30408553
J Pharm Pharm Sci. 2010;13(3):428-42
pubmed: 21092714
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):183-9
pubmed: 17400527
Acta Pharmacol Sin. 2006 Jun;27(6):694-9
pubmed: 16723087
Drug Dev Ind Pharm. 2011 Jan;37(1):15-23
pubmed: 20738181
Pharmaceutics. 2019 Sep 01;11(9):
pubmed: 31480578
J Drug Target. 2016 Sep;24(8):694-702
pubmed: 26942997
Cancer Manag Res. 2019 Oct 16;11:8937-8945
pubmed: 31802936
Pharmaceutics. 2019 Mar 19;11(3):
pubmed: 30893899
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Hepatology. 2011 Feb;53(2):483-92
pubmed: 21274870
Acta Pharm Sin B. 2017 Jan;7(1):91-96
pubmed: 28119813
Cancer Biol Ther. 2011 Nov 1;12(9):797-807
pubmed: 21900746
Curr Pharm Des. 2013;19(3):366-76
pubmed: 22920907
Eur J Drug Metab Pharmacokinet. 2014 Sep;39(3):203-10
pubmed: 24061692
J Control Release. 2017 Feb 28;248:71-95
pubmed: 28088572
Oncol Lett. 2017 Mar;13(3):1041-1047
pubmed: 28454211
Clin Cancer Res. 2015 Feb 15;21(4):833-43
pubmed: 25501124
Oncotarget. 2017 Feb 28;8(9):15364-15376
pubmed: 28157708
Lancet Oncol. 2013 Aug;14(9):e358-69
pubmed: 23896275
Acta Biochim Biophys Sin (Shanghai). 2005 Jul;37(7):501-5
pubmed: 15999212
Eur J Pharmacol. 2016 Mar 15;775:22-34
pubmed: 26852952
Cancer Treat Rev. 2016 Nov;50:247-263
pubmed: 27776286